跳转至内容
Merck
CN

N8289

NBI-31772 hydrate

≥98% (HPLC)

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C17H11NO7 · xH2O
化学文摘社编号:
分子量:
341.27 (anhydrous basis)
UNSPSC Code:
51111800
PubChem Substance ID:
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI

1S/C17H11NO7.H2O/c19-11-2-1-7(4-12(11)20)16(23)15-9-6-14(22)13(21)5-8(9)3-10(18-15)17(24)25;/h1-6,19-22H,(H,24,25);1H2

SMILES string

O.OC(=O)c1cc2cc(O)c(O)cc2c(n1)C(=O)c3ccc(O)c(O)c3

InChI key

QHAUFGIHMBUQKN-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

solid

storage condition

protect from light

storage temp.

−20°C

Biochem/physiol Actions

NBI-31772 is an insulin-like growth factor-1 binding proteins (IGFBPs) inhibitor; IGF-1 potentiator.
NBI-31772 is an insulin-like growth factor-1 binding proteins (IGFBPs) inhibitor; IGF-1 potentiator. NBI-31772 is an air/DMSO DOPA oxidation product, which inhibits IGF binding to IFGFB′s. NBI-31772 displaces IGF-1 from IGF1:IGFBP complex. Thus, it increases circulating level of IGF-1. NBI-31772 does not bind to IGFR.

存储类别

13 - Non Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Jessica E Malberg et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 32(11), 2360-2368 (2007-03-08)
The present studies were conducted to determine if increasing central levels of the neurotrophic factor insulin-like growth factor-1 (IGF-I) either directly or indirectly produces anxiolytic and antidepressant-like effects in the mouse. Central levels of IGF-I can be increased directly, by
X J Liu et al.
The Journal of biological chemistry, 276(35), 32419-32422 (2001-07-11)
Insulin-like growth factor-I (IGF-I) has both metabolic and mitogenic activities mediated through interaction with the type 1 IGF receptor. The circulation of IGF-I in blood and interstitial fluid is not free but bound mostly to a family of six high
Jonathan D Schertzer et al.
The American journal of pathology, 171(4), 1180-1188 (2007-09-08)
Administration of recombinant human insulin-like growth factor-I (rhIGF-I) has beneficial effects in animal models of muscle injury and muscular dystrophy. However, the results of these studies may have been confounded by interactions of rhIGF-I with endogenous IGF-binding proteins (IGFBPs). To

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持